Emerald Advisers Inc. PA Has $2,927,000 Position in Aimmune Therapeutics Inc. (AIMT)
Emerald Advisers Inc. PA boosted its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 0.2% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 270,510 shares of the company’s stock after buying an additional 450 shares during the period. Emerald Advisers Inc. PA’s holdings in Aimmune Therapeutics were worth $2,927,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of AIMT. State Street Corp boosted its position in Aimmune Therapeutics by 8.6% in the first quarter. State Street Corp now owns 158,344 shares of the company’s stock valued at $2,146,000 after buying an additional 12,596 shares during the period. Geode Capital Management LLC boosted its position in Aimmune Therapeutics by 28.2% in the first quarter. Geode Capital Management LLC now owns 92,923 shares of the company’s stock valued at $1,260,000 after buying an additional 20,452 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Aimmune Therapeutics by 9.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 9,617 shares of the company’s stock valued at $130,000 after buying an additional 797 shares during the period. Eagle Asset Management Inc. boosted its position in Aimmune Therapeutics by 12.9% in the second quarter. Eagle Asset Management Inc. now owns 1,988,434 shares of the company’s stock valued at $21,514,000 after buying an additional 227,439 shares during the period. Finally, American Century Companies Inc. boosted its position in Aimmune Therapeutics by 4.5% in the second quarter. American Century Companies Inc. now owns 98,261 shares of the company’s stock valued at $1,063,000 after buying an additional 4,201 shares during the period. 68.87% of the stock is owned by hedge funds and other institutional investors.
Aimmune Therapeutics Inc. (NASDAQ:AIMT) traded up 0.24% during midday trading on Friday, reaching $16.55. The company had a trading volume of 95,599 shares. Aimmune Therapeutics Inc. has a 12 month low of $9.77 and a 12 month high of $22.01. The stock’s market cap is $699.30 million. The firm has a 50-day moving average of $15.53 and a 200-day moving average of $13.65.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.01. On average, equities analysts expect that Aimmune Therapeutics Inc. will post ($1.75) EPS for the current fiscal year.
AIMT has been the subject of several recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a report on Monday, June 13th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $38.00 target price on shares of Aimmune Therapeutics in a report on Tuesday, June 14th. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 19th. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $35.00 target price on shares of Aimmune Therapeutics in a report on Friday, August 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Aimmune Therapeutics has a consensus rating of “Buy” and an average price target of $32.20.
In related news, insider Mary M. Rozenman sold 30,000 shares of Aimmune Therapeutics stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $16.80, for a total transaction of $504,000.00. Following the completion of the transaction, the insider now owns 30,000 shares in the company, valued at $504,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mary M. Rozenman sold 25,000 shares of Aimmune Therapeutics stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $16.80, for a total value of $420,000.00. Following the transaction, the insider now owns 25,000 shares of the company’s stock, valued at approximately $420,000. The disclosure for this sale can be found here. Corporate insiders own 24.56% of the company’s stock.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc. (NASDAQ:AIMT).
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.